Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1496 - FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: a subset analysis from the nation-wide multicenter observational study (JASPAC06)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Pancreatic Cancer


noritoshi Kobayashi


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


N. Kobayashi1, K. Omae2, Y. Horita3, H. Ueno4, N. Mizuno5, K. Uesugi6, K. Sudo7, M. Ozaka8, H. Hayashi9, N. Okano10, K. Kamei11, A. Yamaguchi12, S. Kobayashi13, S. Suzuki14, S. Ishihara15, T. Uchiyama16, A. Todaka17, A. Fukutomi17

Author affiliations

  • 1 Clinical Oncology, Yokohama City University Hospital, 236-004 - Yokohama/JP
  • 2 Clinical Research Promotion Unit, Clinical Research Center, Shizuoka Cancer Center, 4118777 - Sunto-gun/JP
  • 3 Chemotherapy And Internal Medicine, Toyama Prefectural Central Hospital, 9308550 - Toyama/JP
  • 4 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
  • 5 Department Of Gastroenterology, Aichi Cancer Center Hospital, 4648681 - Nagoya/JP
  • 6 Department Of Gastroenterology, National Hospital Organaization Shikoku Cancer Center, 7910280 - Matsuyama/JP
  • 7 Division Of Gastroenterology, Chiba Cancer Center, 2608717 - Chiba/JP
  • 8 Department Of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation For Cancer Research, 1358550 - Tokyo/JP
  • 9 Department Of Gastroenterology And Hepatology, Hokkaido University, 0608648 - Sapporo/JP
  • 10 Department Of Medical Oncology, Kyorin University Faculty of Medicine, 1818611 - Mitaka/JP
  • 11 Department Of Surgery, Kindai University Faculty of Medicine, 5898511 - Osakasayama/JP
  • 12 Department Of Gastroenterology, Kure Medical Center and Chugoku Cancer Center, 7370023 - Kure/JP
  • 13 Department Of Gastroenterology, Division Of Hepatobiliary And Pancreatic Medical Oncology, Kanagawa Cancer Center, 2410815 - Yokohama/JP
  • 14 Department Of Medical Oncology, Yamagata University Faculty of Medicine, 9909585 - Yamagata/JP
  • 15 Department Of Surgery, Fujita Health University, 4701192 - Toyoake/JP
  • 16 Department Of Surgery, Kikugawa General Hospital, 4390022 - Kikugawa/JP
  • 17 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 4118777 - Sunto-gun/JP


Abstract 1496


The data of FOLFIRINOX as second-line chemotherapy in advanced pancreatic cancer are very limited. The JASPAC06 study, a nation-wide multicenter observational study of FOLFIRINOX for the patients with unresectable or recurrent pancreatic cancer as any line treatment, showed the favorable efficacy and safety in Japanese clinical practice.


The subjects were the patients with unresectable/recurrent pancreatic cancer who received FOLFIRINOX as second-line chemotherapy.


Of the 399 evaluable patients in the JASPAC06 study, 44 patients were eligible. Patients characteristics were; median age, 62 years; male, 26(59%); ECOG-PS0/1, 30(68%)/14(32%); disease status recurrent/locally/metastatic, 4(9%)/8(18%)/32(73%); biliary drainage, 11(25%); UGT1A1 status *28 and *6 wild/single heterozygous/homozygous or double heterozygous/unknown, 25(57%)/16(36%)/2(5%)/1(2%). The initial dose was reduced in 28(64%) patients. The median time to treatment failure and the number of cycles were 4.5 (range, 6-573 days) months and 6 cycles (range, 1-13 or more). The major grade 3/4 adverse events were neutropenia in 29(66%) patients, leucopenia in 17(39%), anorexia in 7(16%), febrile neutropenia in 5(11%) and anemia in 5(11%). Fatal adverse event occurred in 1 patient, which was a sudden death. The median overall survival, progression free survival and 1-year survival rate were 10.1 (95%CI, 7.1-13.1), 4.1 (95%CI, 1.5-6.8) months and 41.0%, respectively. The overall response rate and disease control rate were 28% and 65%. The reasons for discontinuation of FOLFIRINOX, excluding 2 patients ongoing treatment, were tumor progression in 38(86%) and toxicity in 4(9%).


It was suggested that FOLFIRINOX as second-line chemotherapy in advanced pancreatic cancer was effective for the patients with good PS and toxicity was similar to that as the first-line treatment.

Clinical trial identification

UMIN000014658 26 July 2014

Legal entity responsible for the study



This trial was supported by Yakult Honsha Co., Ltd. and Daiichi Sankyo Co., Ltd.


H. Ueno: Honoraria: Yakult Honsha Co., Ltd Research Funding: Yakult Honsha Co., Ltd. N. Mizuno: Yakult Honsha Co., Ltd. S. Kobayashi: Honoraria: Yakuly Honsha Co., Ltd. A. Todaka: Honoraria: Yakult Honsha Co., Ltd, Daiichi Sankyo Co., Ltd. A. Fukutomi: Honoraria: Yakult Honsha Co. Ltd, Daiichi Sankyo Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.